Retrospective Descriptive Study on Patients with Low-Intermediate Risk Prostate Cancer Treated with HDR Interstitial Brachytherapy

Ferrero VT and Gabriel SM

Department of Radiotherapy Oncology, Hospital Universitario de San Juan de Alicante, Spain

^*Correspondance to: Vicente Tormo Ferrero 

 PDF  Full Text Research Article | Open Access

Abstract:

Introduction: Primary objective is PSA relapse-free survival. Secondary objectives are description of chronic toxicity and rate of local/regional recurrences/metastases.
Material and Methods: Between 14/06/2016 and 13/02/2023 we included 60 patients diagnosed with low or intermediate risk prostate cancer according to D'Amico criteria. They received interstitial HDR brachytherapy treatment exclusively. Measured chronic toxicity of urinary function, sexual dysfunction, and gastrointestinal function according to CTCAE 5.0 criteria 6 months after starting treatment and annually thereafter. We also monitored PSA values every 6 months and considered biochemical recurrence, according to the Phoenix criteria (PSA NADIR + 2 ng/ml). Statistical analysis was developed by SPSS 29.0.
Results: Median follow-up was 38 months (range: 5 and 80 months). At 38 months and 80 months, PSA relapse-free survival was 98% and 84%, respectively (confidence interval 95%). Chronic gastrointestinal toxicity rates were G0 100%, genitourinary G0 55%, G1 43.3% and G2 1.7% and sexual dysfunction G0 58.3%, G1 8.3% and G2 33.3%. Local relapse rate was 5% and no regional recurrence or distant metastasis appeared.
Discussion: HDR interstitial brachytherapy is a highly effective treatment. A lot of scientific publications have demonstrated high rates of local control and PSA recurrence free survival (97%-85%) for low and intermediate risk prostate cancer. Our results are similar in terms of PSA relapse free survival and toxicity with respect to studies in the scientific literature.

Keywords:

Low-intermediate risk; Prostate cancer; High dose rate; Brachytherapy; Toxicity and PSA relapse-free survival

Cite the Article:

Ferrero VT, Gabriel SM. Retrospective Descriptive Study on Patients with Low-Intermediate Risk Prostate Cancer Treated with HDR Interstitial Brachytherapy. Clin Oncol. 2023;8:2000..